<DOC>
	<DOC>NCT00055302</DOC>
	<brief_summary>The primary objective of this study is to evaluate the safety and efficacy of anastrozole 1 mg given once daily in subjects with McCune-Albright Syndrome.</brief_summary>
	<brief_title>Arimidex in McCune Albright Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Fibrous Dysplasia, Polyostotic</mesh_term>
	<mesh_term>Anastrozole</mesh_term>
	<criteria>informed written consent of parent/legal guardian and subject assent (as needed by local requirements) females less than or equal to 10 years of age diagnosed with McCuneAlbright Syndrome have progressive precocious puberty Any one of the following is regarded as a criterion for exclusion from the study: any prior treatment of MAS associated with progressive precocious puberty with a third generation aromatase inhibitor (anastrozole, letrozole, exemestane) in which no clinical response was seen concomitant treatment of precocious puberty associated with MAS, with the exception of bisphosphonates for polyostotic fibrous dysplasia and LHRH analogues in the case of central precocious puberty liver function tests at screening visit (AST, ALT) &gt; or = 3x the upper limit of the reference range for age known hypersensitivity to any component of study medication</criteria>
	<gender>Female</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2015</verification_date>
	<keyword>vaginal bleeding</keyword>
	<keyword>advanced bone age</keyword>
	<keyword>fibrous dysplasia</keyword>
	<keyword>MAS</keyword>
	<keyword>McCune-Albright Syndrome</keyword>
</DOC>